Trazodone Hydrochloride 150 Mg Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Trazodone Hydrochloride 150 mg Tablets.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 150 mg trazodone hydrochloride
Excipient with known effects: Each tablet contains 176 mg of lactose monohydrate. For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Film coated tablets.
Dusty mauve film coated tablet debossed “TO” on one side with “G” on the reverse.
150
4. CLINICAL PARTICULARS
4.1. Therapeutic indications
Trazodone relieves symptoms of all types of depression including depressive illness accompanied by anxiety.
4.2. Posology and method of administration Posology
Depression
Adult
Initially 150 mg/day in divided doses after food or as a single dose on retiring.
This may be increased up to 300 mg/day in a single or divided doses. The major portion of a divided dose should be taken when retiring. The dose may be further increased to 600 mg/day in divided doses in hospitalised patients.
Elderly
For very elderly patients or frail patients, the recommended initial starting dose is reduced to 100 mg/day in divided doses or as a single night time dose (see section 4.4). This may be incrementally increased, under supervision, according to efficacy and tolerance. In general, single doses above 100 mg should be avoided in these patients. It is unlikely that 300 mg/day will be exceeded.
Paediatric population
Trazodone is not recommended for use in children below the age of 18 years due to a lack of data on safety.
Depression accompanied by Anxiety
As for depression
Anxiety 75 mg increasing to 300 mg/day as necessary.
A decrease of the side-effects (increase of the resorption and decrease of the peak plasma concentration) can be reached by taking trazodone hydrochloride after a meal.
Current psychiatric opinion is that withdrawal of the medication should be gradual.
Patients with hepatic impairment
Trazodone undergoes extensive hepatic metabolism, see section 5.2, and has also been associated with hepatotoxicity, see sections 4.4 and 4.8. Therefore caution should be exercised when prescribing for patients with hepatic impairment, particularly in cases of severe hepatic impairment. Periodic monitoring of liver function may be considered.
Patients with renal impairment
No dosage adjustment is usually necessary, but caution should be exercised when prescribing for patients with severe renal impairment (see also sections 4.4 and 5.2).
Method of administration
For oral administration.
4.3. Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Alcohol intoxication and intoxication with hypnotics.
Acute myocardial infarction.
4.4 Special warnings and precautions for use
Paediatric population
Trazodone should not be used in children and adolescents under 18. Suicidal behaviour (suicidal attempt and suicidal planning) and hostility (essentially aggressiveness, opposing behaviour and anger) have been observed in a clinical study on children and adolescents treated with antidepressant more frequently than with placebo. Moreover, long-term safety data on children and adolescents regarding growth, maturation and cognitive and behavioural development are not available.
Suicide/suicidal thoughts or clinical worsening
Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
Other psychiatric conditions for which trazodone is prescribed can also be associated with an increased risk of suicide related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.
Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
To minimise the potential risk of suicide attempts, particularly at therapy initiation, only restricted quantities of trazodone should be prescribed at each occasion.
It is recommended that careful dosing and regular monitoring is adopted in patients with the following conditions:
• Epilepsy, specifically abrupt increases or decreases of dosage should be avoided
• Patients with hepatic or renal impairment, particularly if severe
• Patients with cardiac disease, such as angina pectoris, conduction disorders or AV blocks of different degree, recent myocardial infarction
• Hyperthyroidism
• Micturition disorders, such as prostate hypertrophy, although problems would not be anticipated as the anticholinergic effect of trazodone is only minor
• Acute narrow angle glaucoma, raised intra-ocular pressure, although major changes would not be anticipated due to the minor anticholinergic effect of trazodone
Should jaundice occur in a patient, trazodone therapy must be withdrawn.
Severe hepatic disorders with potential fatal outcome have been reported with trazodone use (see section 4.8). Patients should be instructed to report immediately signs such as asthenia, anorexia, nausea, vomiting, abdominal pain or icterus to a physician. Investigations including clinical examination and biological assessment of liver function should be undertaken immediately, and withdrawal of trazodone therapy be considered.
Administration of antidepressants in patients with schizophrenia or other psychotic disorders may result in a possible worsening of psychotic symptoms. Paranoid thoughts may be intensified. During therapy with trazodone a depressive phase can change from a manic-depressive psychosis into a manic phase. In that case trazodone must be stopped.
Interactions in terms of serotonin syndrome/malignant neuroleptic syndrome have been described in case of concomitant use of other serotonergically acting substances like other antidepressants (e.g. tricyclic antidepressants, SSRI’s, SNRI’s and MAO-inhibitors) and neuroleptics. Malignant neuroleptic syndromes with fatal outcome have been reported in cases of coadministration with neuroleptics, for which this syndrome is a known possible adverse drug reaction. See sections 4.5 and 4.8 for further information.
Since agranulocytosis may clinically reveal itself with influenza-like symptoms, sore throat and fever, in these cases it is recommended to check haematology.
Hypotension, including orthostatic hypotension and syncope, has been reported to occur in patients receiving trazodone. Concomitant administration of antihypertensive therapy with trazodone may require a reduction in the dose of the antihypertensive drug.
Elderly patients may more often experience orthostatic hypotension, somnolence, and other anticholinergic effects of trazodone. Careful consideration should be given to the potential for additive effects with concomitant medication use such as with other psychotropics or antihypertensives or in the presence of risk factors such as comorbid disease, which may exacerbate these reactions. It is recommended that the patient/carer is informed of the potential for these reactions and monitored closely for such effects following initiation of therapy, prior to and following upward dose titration.
Following therapy with trazodone, particularly for a prolonged period, an incremental dosage reduction to withdrawal is recommended, to minimise the occurrence of withdrawal symptoms, characterised by nausea, headache and malaise.
There is no evidence that trazodone hydrochloride possesses any addictive properties.
As with other antidepressant drugs, cases of QT interval prolongation have been reported with trazodone very rarely. Caution is advised when prescribing trazodone with medicinal products known to prolong QT interval. Trazodone should be used with caution in patients with known cardiovascular disease including those associated with prolongation of the QT interval.
Potent CYP3A4 inhibitors may lead to increases in trazodone serum levels. See section 4.5 for further information.
As with other drugs with alpha-adrenolytic activity, trazodone has very rarely been associated with priapism. This may be treated with an intracavernosum injection of an alpha-adrenergic agent such as adrenaline or metaraminol. However there are reports of trazodone-induced priapism which have required surgical intervention or led to permanent sexual dysfunction. Patients developing this suspected adverse reaction should cease trazodone immediately.
As this medicinal product contains lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5. Interaction with other medicinal products and other forms of interaction
General: The sedative effects of antipsychotics, hypnotics, sedatives, anxiolytics and antihistaminic drugs may be intensified; dosage reduction is recommended in such instances.
The metabolism of antidepressants is accelerated due to hepatic effects by oral contraceptives, phenytoin, carbamazepine and barbiturates. The metabolism of antidepressants is inhibited by cimetidine and some other antipsychotics.
CYP3A4 inhibitors: Drug metabolism studies in vitro are indicative that there is a potential for drug interactions when trazodone is given with potent CYP3A4 inhibitors such as erythromycin, ketoconazole, itraconazole, ritonavir, indinavir and nefazodone. It is likely that potent CYP3A4 inhibitors may lead to substantial increases in trazodone plasma concentrations with the potential for adverse effects. Exposure to ritonavir during initiation or resumption of treatment in patients receiving trazodone will increase the potential for excessive sedation, cardiovascular, and gastrointestinal effects. It has been confirmed in in-vivo-studies in healthy volunteers, that a ritonavir dose of 200 mg BID increased the plasma levels of trazodone by greater than two-fold, leading to nausea, syncope and hypotension. If trazodone is used with a potent CYP3A4 inhibitor, a lower dose of trazodone should be considered. However, co-administration of trazodone and potent CYP3A4 inhibitors should be avoided where possible.
Carbamazepine reduced plasma concentrations of trazodone when coadministered. Concomitant use of carbamazepine 400 mg daily led to a decrease of plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine of 76% and 60%, respectively. Patients should be closely monitored to see if there is a need for an increased dose of trazodone when taken with carbamazepine.
Trazodone may enhance the effects of muscle relaxants and volatile anaesthetics, and caution should be exercised in such instances. Similar considerations apply to combined administration with sedative and anti-depressants drugs, including alcohol. Trazodone intensifies the sedative effects of alcohol. Alcohol should be avoided during trazodone therapy.
Trazodone has been well tolerated in depressed schizophrenic patients receiving standard phenothiazine therapy and also in depressed parkinsonian patients receiving therapy with levodopa. Antidepressants can accelerate the metabolism of levodopa.
Tricyclic antidepressants: concurrent administration should be avoided due to the risk of interaction. Serotonin syndrome and cardiovascular side effects are possible and should be forewarned.
Fluoxetine: rare cases have been reported of elevated trazodone plasma levels and adverse effects when trazodone had been combined with fluoxetine, a CYP1A2/2D6 inhibitor. The mechanism underlying a pharmacokinetic interaction is not fully understood. A pharmacodynamic interaction (serotonin syndrome) could not be excluded.
Monoamine oxidase inhibitors: Possible interactions with monoamine oxidase inhibitors have occasionally been reported. Although some clinicians do give both concurrently, use of trazodone concomitantly with MAOI’s, or within two weeks from discontinuation of these substances is not recommended. The administration of MAOI’s within one week since discontinuation of trazodone treatment is not recommended either.
Phenothiazines: Severe orthostatic hypotension has been observed in cases of concomitant use with phenothiazines, like e.g. chlorpromazine, fluphenazine, levomepromazine and perphenazine.
Other: Concomitant use of Trazodone with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Caution should be used when these drugs are coadministered with trazodone.
Since trazodone is only a weak inhibitor of noradrenaline re-uptake and does not modify the blood pressure response to tyramine, interference with the hypotensive action of guanethidine-like compounds is unlikely. However, studies in laboratory animals suggest that trazodone may inhibit most of the acute actions of clonidine. In the case of other types of antihypertensive drug, although no clinical interactions have been reported, the possibility of potentiation should be considered.
Undesirable effects may be more frequent when trazodone is administered together with preparations containing Hypericum perforatum (St. Johns wort).
There have been reports of changes in prothrombin time in patients concomitantly receiving trazodone and warfarin.
Concurrent use of trazodone may result in elevated serum levels of digoxin or phenytoin. Monitoring the serum levels should be considered in these patients.
4.6. Fertility, pregnancy and lactation
Pregnancy
Data on a limited number (< 200) of exposed pregnancies indicate no adverse effects of trazodone on pregnancy or on the health of the foetus/newborn child. To date, no other relevant epidemiological data are available. The safety of trazodone in human pregnancy has not been established. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development at therapeutic doses (see section 5.3). On basic principles, therefore, its use during the first trimester should be avoided.
Caution should be exercised when prescribing to pregnant women. When trazodone is used until delivery, newborns should be monitored for the occurrence of withdrawal symptoms.
Breast-feeding
Limited data indicate that excretion of trazodone in human breast milk is low, but levels of the active metabolite are not known. Due to the paucity of data, a decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with trazodone should be made taking into account the benefit of trazodone therapy to the woman.
4.7. Effects on ability to drive and use machines
Trazodone has minor or moderate influence on the ability to drive and use machines. As with all other drugs acting on the central nervous system, patients should be cautioned against the risks of driving or operating machinery until they are sure they are not affected by drowsiness, sedation, dizziness, confusional states or blurred vision.
4.8. Undesirable effects
Cases of suicidal ideation and suicidal behaviours have been reported during trazodone therapy or early after treatment discontinuation (see section 4.4).
Trazodone has had no effect on arterial blood pCO2 or pO2 levels in patients with severe respiratory insufficiency due to chronic bronchial or pulmonary disease.
The following symptoms, some of which are commonly reported in cases of untreated depression, have also been recorded in patients receiving trazodone therapy.
|
MedDRA System Organ Class |
Frequency not known (cannot be estimated from the available data) |
|
Blood and lymphatic system disorders |
Blood dyscrasias (including agranulocytosis, thrombocytopenia, eosinophilia, leucopenia and anaemia) |
|
Immune system disorders |
Allergic reactions |
|
Endocrine disorders |
Syndrome of Inappropriate Antidiuretic Hormone Secretion |
|
Metabolism and nutrition disorders |
Hyponatraemia1, weight loss, anorexia, increased appetite |
|
Psychiatric disorders |
Suicidal ideation or suicidal behaviours , confusional state, insomnia, disorientation, mania, anxiety, nervousness, agitation (very occasionally exacerbating to delirium), delusion, aggressive reaction, hallucinations, nightmares, libido decreased, withdrawal syndrome |
|
Nervous system disorders |
Serotonin syndrome, convulsion, neuroleptic malignant syndrome, dizziness, vertigo, headache, drowsiness , restlessness, decreased alertness, tremor, blurred vision, memory disturbance, myoclonus, expressive aphasia, paraesthesia, dystonia, taste altered |
|
Cardiac disorders |
Cardiac arrhythmias4 (including Torsade de Pointes, |
|
MedDRA System Organ Class |
Frequency not known (cannot be estimated from the available data) |
|
palpitations, premature ventricular contractions, ventricular couplets, ventricular tachycardia), bradycardia, tachycardia, ECG abnormalities (QT prolongation)2 | |
|
Vascular disorders |
Orthostatic hypotension, hypertension, syncope |
|
Respiratory, thoracic and mediastinal disorders |
Nasal congestion, dyspnoea |
|
Gastrointestinal disorders |
Nausea, vomiting, dry mouth, constipation, diarrhoea, dyspepsia, stomach pain, gastroenteritis, increased salivation, paralytic ileus |
|
Hepatobiliary disorders |
Hepatic function abnormalities (including jaundice and hepatocellular damage)5, cholestasis intrahepatic, severe hepatic disorders such as hepatitis/fulminant hepatitis and hepatic failure with potentially fatal outcome |
|
Skin and subcutaneous tissue disorders |
Skin rash, pruritus, hyperhidrosis |
|
Musculoskeletal and connective tissue disorders |
Pain in limb, back pain, myalgia, arthralgia |
|
Renal and urinary disorders |
Micturition disorders |
|
Reproductive system and breast disorders |
Priapism6 |
|
General disorders and administration site conditions |
Weakness, oedema, influenza-like symptoms, fatigue, chest pain, fever |
|
Investigations |
Elevated liver enzymes |
1 Fluid and electrolyte status should be monitored in symptomatic patients.
2 See also section 4.4
Trazodone is a sedative antidepressant and drowsiness, sometimes experienced during the first days of treatment, usually disappears on continued therapy.
4 Studies in animals have shown that trazodone is less cardiotoxic than the tricyclic antidepressants, and clinical studies suggest that the drug may be less likely to cause cardiac arrhythmias in man. Clinical studies in patients with pre-existing cardiac disease indicate that trazodone may be arrhythmogenic in some patients in that population.
5 Adverse effects on hepatic function, sometimes severe, have been rarely reported. Should such effects occur, trazodone should be immediately discontinued.
6 See also section 4.4
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Symptoms
The most frequently reported reactions to overdose have included drowsiness, dizziness, nausea and vomiting. In more serious cases coma, tachycardia, hypotension, hyponatraemia, convulsions and respiratory failure have been reported. Cardiac features may include bradycardia, QT prolongation and torsade de pointes. Symptoms may appear within 24 hours or more after overdose.
Overdoses of trazodone in combination with other antidepressants may cause serotonin syndrome.
Management
There is no specific antidote to trazodone. Activated charcoal should be considered in adults who have ingested more than 1 g trazodone, or in children who have ingested more than 150 mg trazodone within 1 hour of presentation. Alternatively, in adults, gastric lavage may be considered within 1 hour of ingestion of a potentially life-threatening overdose.
Observe for at least 6 hours after ingestion (or 12 hours if a sustained release preparation has been taken). Monitor BP, pulse and Glasgow Coma Scale (GCS). Monitor oxygen saturation if GCS is reduced. Cardiac monitoring is appropriate in symptomatic patients.
Single brief convulsions do not require treatment. Control frequent or prolonged convulsions with intravenous diazepam (0.1-0.3 mg/kg body weight) or lorazepam (4 mg in an adult and 0.05 mg/kg in a child). If these measures do not control the fits an intravenous infusion of phenytoin may be useful. Give oxygen and correct acid base and metabolic disturbances as required.
Treatment should be symptomatic and supportive in the case of hypotension and excessive sedation. If severe hypotension persists consider use of inotropes, e.g. dopamine or dobutamine.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: other antidepressants ATC Code: N06A X05
Trazodone is a potent antidepressant, it also has anxiety reducing activity. Trazodone is triazolopyridine derivative chemically unrelated to known tricyclic, tetracyclic and other antidepressant agents. It has negligible effect on noradrenaline re-uptake mechanisms. Whilst the mode of action of trazodone is not known precisely, it antidepressant activity may concern noradrenergic potentiation by mechanisms other than uptake blockade. A central antiserotonin effect may account for the drug’s anxiety reducing properties.
5.2. Pharmacokinetic properties
Trazodone is rapidly absorbed from the gastrointestinal tract and extensively metabolised. Paths of metabolism of trazodone include n-oxidation and hydroxylation. The metabolite m-chlorophenylpiperazine is active. Trazodone is excreted in the urine almost entirely in the
form of its metabolites, either in free or in conjugated form. The elimination of trazodone is biphasic, with a terminal elimination half-life of 5 to 13 hours. Trazodone is excreted in breast milk.
There was an approximate two-fold increase in terminal phase half-life and significantly higher plasma concentrations of trazodone in 10 subjects aged 65-74 years compared with 12 subjects aged 23-39 years following a 100 mg dose of trazodone. It was suggested that there is an age-related reduction in hepatic metabolism of trazodone.
In vitro studies in human liver microsomes show that trazodone is metabolised by cytochrome P4503A4 (CYP3A4) to form m-chlorophenylpiperazine. Whilst significant, the role of this pathway in the total clearance of trazodone in vivo has not been fully determined.
5.3. Preclinical safety data
There are no preclinical data relevant to the prescriber, which is not presented in other areas of the summary of medicinal product characteristics.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Microcrystalline Cellulose Maize Starch Lactose Monohydrate Crospovidone Povidone K30 Magnesium Stearate
Opadry Contents
Titanium Dioxide (E171), Lactose Monohydrate, Hydroxypropylmethylcellulose (HPMC) 2910 15cp (E464), Polyethylene Glycol, Hydroxypropylmethylcellulose (HPMC) 2910 3cp (E464), Hydroxypropylmethylcellulose (HPMC) 2910 50cp (E464), Iron Oxide Red (E172), Indigo Carmine aluminium Lake (E132) FD & C Blue No. 2., Iron Oxide Yellow (E172).
6.2. Incompatibilities
Not known.
6.3. Shelf life
2 years.
6.4. Special precautions for storage
No special precautions for storage.
6.5. Nature and contents of container
Polyvinyldene chloride coated polyvinylchloride (60gsm), aluminium foil blisters.
Polypropylene tablet containers with polyethylene caps (with optional polyethylene ullage filler).
High density polyethylene (HDPE) bottle with polyethylene snap closure.
Blister pack sizes (may or may not be in calendar packs):- 20, 28, 30, 56, 84, 90, 100, 112, 120, 168 and 180.
HDPE and Polypropylene pack sizes: - 5, 7, 10, 15, 20, 21, 25, 28, 30, 50, 56, 60, 84, 90, 100, 112, 120, 168, 180, 200, 250 and 500.
Not all pack sizes may be marketed.
6.6. Special precautions for disposal and other handling
No special requirements for disposal.
7. MARKETING AUTHORISATION HOLDER
Generics [UK] Limited t/a Mylan
Station Close
Potters Bar
Hertfordshire
EN6 1TL
United Kingdom
8. MARKETING AUTHORISATION NUMBER(S)
PL 04569/0398
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 12 February 2001 Date of latest renewal: 23rd March 2009